News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dicerna Pharmaceuticals (DRNA) Announces Closing Of Initial Public Offering And Exercise Of Option To Purchase Additional Shares


2/5/2014 5:09:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) today announced the closing of its initial public offering of 6,900,000 shares of common stock, including 900,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, at a public offering price of $15.00 per share, before underwriting discounts. The aggregate net proceeds to Dicerna, after deducting underwriting discounts and commissions and estimated offering expenses, will be approximately $92.9 million. Jefferies LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated acted as joint book-running managers for the offering. Robert W. Baird & Co. Incorporated acted as co-lead manager for the offering.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES